Xintela
0.265 SEK +3.92%1 investor is following this company
Xintela is active in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage, and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes in the surface of cells, which enables the identification of the stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.
Revenue
80K
EBIT %
-71,550 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
XINT
Daily low / high price
0.255 / 0.291
SEK
Market cap
150.26M SEK
Turnover
8.44K SEK
Volume
31K
Latest videos
Financial calendar
General meeting
08.05.2024
Interim report
24.05.2024
Interim report
30.08.2024
Interim report
22.11.2024
Annual report
28.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 54.2 % | 54.2 % |
Avanza Pension | 5.0 % | 5.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Xintela AB, Investor Day, 2024
Västra Hamnen Market Focus: Xintela: Awaiting results in trials and discussions
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools